Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma arising from the ovary, fallopian tubes, or peritoneum (i.e., peritoneal serous papillary adenocarcinoma)
Received prior treatment with either cisplatin or carboplatin in combination with paclitaxel or docetaxel as first-line chemotherapy
Radiographic evidence of progressive disease and/or a doubling of CA-125 levels ≥ 70 IU/mL following first-line chemotherapy
Measurable disease as defined by RECIST criteria
No CNS metastases

PATIENT CHARACTERISTICS:

ECOG performance status 0-2
Absolute neutrophil count ≥ 1,500/μL
Hemoglobin ≥ 9.5 g/dL
Platelets > 100,000/μL
Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
Total bilirubin ≤ 1.5 times ULN
AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if liver metastases are present)
LVEF ≥ 50% by MUGA
Not pregnant or nursing
Negative pregnancy test
Surgically sterile or must use effective contraception
No known HIV positivity or AIDS
No uncontrolled heart disease, diabetes, or other medical condition that would place the patient at unacceptably high risk for toxicity
No New York Heart Association class I-IV heart failure

Exclusion Criteria:

Not specified

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from all prior toxicities to ≤ grade 1 by NCI-CTC Version 2 criteria
No other prior systemic therapies for this cancer except cisplatin or carboplatin in combination with paclitaxel or docetaxel as first-line chemotherapy
More than 4 weeks since prior chemotherapy
No concurrent anticancer therapy